Researchers have proposed a radical change in the way Alzheimer’s disease is defined, focusing on biological changes in the body, rather than clinical symptoms such as memory loss and cognitive decline.
Genomic data can have a significant effect on other areas of society. Insurance premiums, familial impact, identification. As we enter the genomic era, policy will need to reflect these new considerations.
Critically ill infants in the Australian state of Victoria are now to be given access to rapid genomic sequencing under a new government-funded programme.
Patient advocacy groups take in millions from drugmakers. Is there a payback? Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
The FDA has approved Seattle Genetics’ Hodgkin’s lymphoma treatment, which is the first to be approved to treat the disease in over 40 years.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
The World Health Organisation (WHO) has put scientists and health workers around the globe on alert for a new and potentially deadly pathogen – Disease X.
The HHS civil rights division refocuses on the rights of health care providers who have moral objections to treatments such as abortion or sterilization, alarming critics.